Anticoagulation with a new oral anticoagulant in heart transplant recipients

Rivaroxaban is now accepted for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, and treatment and secondary prevention of deep vein thrombosis and pulmonary embolism. Nothing is known about the use of this new anticoagulant in transplanted patients. Here we report a series of heart transplant recipients treated with rivaroxaban and followed at our transplantation center.

Source: International Journal of Cardiology - July 25, 2013 Category: Cardiology Authors: Pierre Ambrosi, Bernard Kreitmann, William Cohen, Gilbert Habib, Pierre Morange Tags: Letters to the Editor Source Type: research